First Cancer treatment injection approved now

Hundreds of patients in England will receive a cancer-treating injection for the first time from Britain’s government-run national health system, which might reduce recovery times by as much as 75 percent.Following authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England said on Tuesday, August 29, that hundreds of eligible patients receiving atezolizumab immunotherapy were going to have their injections “under the skin,” which will allow cancer teams to spend more time treating other patients.Patients typically receive atezolizumab intravenously through an IV drip, but many will now receive the immunotherapy through an injection.

The medication, also known as Tecentriq, is used to treat a variety of cancers, including bladder, lung, breast, and liver tumours. In England, it is administered to roughly 3,600 patients yearly.
“This approval will not only allow us to deliver convenient and faster care for our patients, but it will also enable our teams to treat more patients throughout the day,” said Dr. Alexander Martin, a consultant oncologist at West Suffolk NHS Foundation Trust, in a statement to Reuters.This immunotherapy drug, produced by Genentech, a division of Roche, strengthens the patient’s immune system so it can find and destroy cancer cells. Patients on the NHS who have been diagnosed with various cancers, such as lung, breast, liver, and bladder cancers, are being given the treatment through transfusion.

Medical director for Roche Marius Scholtz stated: “Injecting Tecentriq under the skin offers a speedier treatment option as it takes around seven minutes, compared with 30 to 60 minutes for the existing procedure of an intravenous infusion of Tecentriq.We are thrilled that subcutaneous PD-L1 cancer immunotherapy injections are now available to NHS patients in England.